Wet AMD sufferers unaware of pre-existing AMD

Article

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Itay Chowers, MD of the Hadassah-Hebrew University Medical Center, Israel and colleagues conducted a retrospective analysis of NVAMD subjects (n=268) and compared characteristics between those subjects who were aware of their AMD before the NVAMD diagnosis (n=83), and those who were not (n=185).

The researchers found that there were no significant differences between the two groups in terms of demographic characteristics, visual acuity, lesion size and lesion composition. Patients who were not previously aware of their AMD were more likely to have a history of smoking (41%) than those who were aware (26%); patients with a positive family history of AMD were more likely to be aware of their own AMD before the NVAMD diagnosis (20%) than those who did not (10%).

The team concluded that the majority of patients receiving an NVAMD diagnosis were previously unaware that they had AMD, although early AMD detection may not entail detection of treatable choroidal neovascularization lesions.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.